BRISTOL-MYERS SQUIBB CO (1BMY.MI) Stock Price & Overview
BIT:1BMY • US1101221083
Current stock price
The current stock price of 1BMY.MI is 52.8 EUR. Today 1BMY.MI is down by -1.2%. In the past month the price increased by 25.3%.
1BMY.MI Key Statistics
- Market Cap
- 107.526B
- P/E
- 9.91
- Fwd P/E
- 10.02
- EPS (TTM)
- 5.33
- Dividend Yield
- 4.27%
1BMY.MI Stock Performance
1BMY.MI Stock Chart
1BMY.MI Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to 1BMY.MI.
1BMY.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to 1BMY.MI. 1BMY.MI has an excellent profitability rating, but there are some minor concerns on its financial health.
1BMY.MI Earnings
On February 5, 2026 1BMY.MI reported an EPS of 1.26 and a revenue of 12.50B. The company beat EPS expectations (11.85% surprise) and beat revenue expectations (0.79% surprise).
1BMY.MI Forecast & Estimates
36 analysts have analysed 1BMY.MI and the average price target is 52.72 EUR. This implies a price decrease of -0.16% is expected in the next year compared to the current price of 52.8.
For the next year, analysts expect an EPS growth of -1.05% and a revenue growth -1.88% for 1BMY.MI
1BMY.MI Groups
Sector & Classification
1BMY.MI Financial Highlights
Over the last trailing twelve months 1BMY.MI reported a non-GAAP Earnings per Share(EPS) of 5.33. The EPS increased by 439.47% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 14.64% | ||
| ROA | 7.83% | ||
| ROE | 38.19% | ||
| Debt/Equity | 2.33 |
1BMY.MI Ownership
1BMY.MI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1SAN | SANOFI | 9.4 | 97.617B | ||
| SAN | SANOFI | 9.27 | 97.205B | ||
| SNW | SANOFI | 9.36 | 97.193B | ||
| UCB | UCB SA | 25.81 | 53.49B | ||
| UNC | UCB SA | 25.91 | 53.218B | ||
| MRK | MERCK KGAA | 14.09 | 48.63B | ||
| 1MRK | MERCK KGAA | 13.62 | 46.695B | ||
| 1BAYN | BAYER AG-REG | 9.21 | 39.808B | ||
| BAYN | BAYER AG-REG | 9.15 | 39.415B | ||
| IPN | IPSEN | 13.34 | 14.315B | ||
| REC | RECORDATI INDUSTRIA CHIMICA | 16.3 | 10.214B | ||
| TUB | FINANCIERE DE TUBIZE | N/A | 10.059B | ||
| VIRP | VIRBAC SA | 16.6 | 3.02B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Milan Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About 1BMY.MI
Company Profile
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in Princeton, New Jersey and currently employs 32,500 full-time employees. The company is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
Company Info
IPO: 1980-03-17
BRISTOL-MYERS SQUIBB CO
Route 206 And Province Line Road
Princeton NEW JERSEY US
Employees: 32500
Phone: 13026587581
BRISTOL-MYERS SQUIBB CO / 1BMY.MI FAQ
Can you describe the business of BRISTOL-MYERS SQUIBB CO?
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in Princeton, New Jersey and currently employs 32,500 full-time employees. The company is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
Can you provide the latest stock price for BRISTOL-MYERS SQUIBB CO?
The current stock price of 1BMY.MI is 52.8 EUR. The price decreased by -1.2% in the last trading session.
Does 1BMY stock pay dividends?
BRISTOL-MYERS SQUIBB CO (1BMY.MI) has a dividend yield of 4.27%. The yearly dividend amount is currently 2.19.
What is the ChartMill technical and fundamental rating of 1BMY stock?
1BMY.MI has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
On which exchange is 1BMY.MI stock listed?
1BMY.MI stock is listed on the Euronext Milan exchange.
Can you provide the market cap for BRISTOL-MYERS SQUIBB CO?
BRISTOL-MYERS SQUIBB CO (1BMY.MI) has a market capitalization of 107.53B EUR. This makes 1BMY.MI a Large Cap stock.